Literature DB >> 8464238

Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques.

A Neubauer1, M He, C A Schmidt, D Huhn, E T Liu.   

Abstract

Rearrangements of the c-abl protooncogene and the bcr-gene are found in > 90% of patients in chronic phase of chronic myelogenous leukemia (CML). The molecular events leading to blast crisis, however, have not been well characterized. Gross alterations of the p53 gene have been detected in 30% of patients with blast crisis. Since point mutations in the p53 gene appear to be important in the process of transformation in many epithelial tumors, we looked for these mutations in the critical regions of the p53 gene (exons 4, 5, 6, 7, and 8). We used the polymerase chain reaction (PCR), direct sequencing, differential PCR, and single strand conformation polymorphism (SSCP) analysis to detect mutations of the p53 gene in samples from 21 patients with CML blast crisis. Two of 21 patients exhibited an intragenic deletion or rearrangement in p53. In addition, these patients were homozygous for the mutant p53 allele. No mutations were found in the p53 gene of the remaining 19 patients. However, sequencing of the CML blast crisis cell line, K562, revealed an insertion of a C at base position 956 within the fifth exon, causing a frame shift mutation and an early translational stop at codon 148. We conclude that, in contrast to solid tumors, mutations in exons 4-8 of p53 are not frequently seen in primary samples from CML blast crisis. However, deletions and/or rearrangements within the p53 gene do occur and may contribute to the progression from chronic phase to blast crisis in a limited number of patients with CML.

Entities:  

Mesh:

Year:  1993        PMID: 8464238

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  12 in total

1.  Fluorescence-based mutation detection. Single-strand conformation polymorphism analysis (F-SSCP).

Authors:  J S Ellison
Journal:  Mol Biotechnol       Date:  1996-02       Impact factor: 2.695

Review 2.  Genetic events other than BCR-ABL1.

Authors:  Paolo Neviani
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

3.  Frequency of TP53 Mutations and its Impact on Drug Sensitivity in Acute Myeloid Leukemia?

Authors:  Ankur Shah; Claire Seedhouse
Journal:  Indian J Clin Biochem       Date:  2012-03-24

4.  p53 Isoforms: An Intracellular Microprocessor?

Authors:  Marie P Khoury; Jean-Christophe Bourdon
Journal:  Genes Cancer       Date:  2011-04

Review 5.  Biotherapy of chronic myelogenous leukemia.

Authors:  W E Aulitzky; C Peschel; F Schneller; C Huber
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

6.  P53 tumor suppressor gene in chronic myelogenous leukemia: a sequential study.

Authors:  A Rovira; A Urbano-Ispizua; F Cervantes; M Rozman; J L Vives-Corrons; E Montserrat; C Rozman
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

7.  Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia.

Authors:  G Gaidano; A Serra; A Guerrasio; G Rege-Cambrin; U Mazza; G Saglio
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

8.  Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.

Authors:  Andreas Neubauer; Kati Maharry; Krzysztof Mrózek; Christian Thiede; Guido Marcucci; Peter Paschka; Robert J Mayer; Richard A Larson; Edison T Liu; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2008-06-16       Impact factor: 44.544

9.  Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells.

Authors:  J Schwaller; H P Koeffler; G Niklaus; P Loetscher; S Nagel; M F Fey; A Tobler
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

10.  Detection of p53 mutations using nonradioactive SSCP analysis: p53 is not frequently mutated in myelodysplastic syndromes (MDS).

Authors:  A Neubauer; C Brendel; D Vogel; C A Schmidt; I Heide; D Huhn
Journal:  Ann Hematol       Date:  1993-11       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.